{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:35:57Z","timestamp":1793957757255,"version":"4.8.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":1782,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Ohio State University College of Medicine Roessler Research Scholarship"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13311-018-00679-z","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T09:42:25Z","timestamp":1539855745000},"page":"872-884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Myotonic Dystrophies: Targeting Therapies for Multisystem Disease"],"prefix":"10.1016","volume":"15","author":[{"given":"Samantha","family":"LoRusso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. David","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-018-00679-z_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases\u2014a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-00679-z_bib2","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ejhg.2011.23","article-title":"Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland","volume":"19","author":"Suominen","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"10.1007\/s13311-018-00679-z_bib3","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.1062125","article-title":"Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9","volume":"293","author":"Liquori","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-018-00679-z_bib4","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00415-013-6993-0","article-title":"Diagnostic odyssey of patients with myotonic dystrophy","volume":"260","author":"Hilbert","year":"2013","journal-title":"J Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neurol.2016.08.003","article-title":"Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification","volume":"172","author":"De Antonio","year":"2016","journal-title":"Rev Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5409\/wjcp.v4.i4.66","article-title":"Congenital and childhood myotonic dystrophy: current aspects of disease and future directions","volume":"4","author":"Ho","year":"2015","journal-title":"World J Clin Pediatr"},{"key":"10.1007\/s13311-018-00679-z_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000444469","article-title":"Knowledge of sub-types important to understanding of the prevalence of myotonic dystrophy","volume":"46","author":"Theadom","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.1007\/s13311-018-00679-z_bib8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","article-title":"Myotonic dystrophy","volume":"32","author":"Thornton","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1007\/s13311-018-00679-z_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/joor.12534","article-title":"Temporomandibular dysfunction in adult patients with myotonic dystrophy (DM1)","volume":"44","author":"Mejersjo","year":"2017","journal-title":"J Oral Rehabil"},{"key":"10.1007\/s13311-018-00679-z_bib10","doi-asserted-by":"crossref","first-page":"120-5.e1","DOI":"10.1016\/j.jpeds.2012.12.070","article-title":"Congenital myotonic dystrophy: Canadian population-based surveillance study","volume":"163","author":"Campbell","year":"2013","journal-title":"J Pediatr"},{"key":"10.1007\/s13311-018-00679-z_bib11","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/B978-0-444-59565-2.00009-5","article-title":"Congenital and infantile myotonic dystrophy","volume":"113","author":"Echenne","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148264","article-title":"Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study","volume":"11","author":"Dogan","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-018-00679-z_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1212\/01.WNL.0000054481.84978.F9","article-title":"Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum","volume":"60","author":"Day","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-00679-z_bib14","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1007\/s00415-017-8653-2","article-title":"Assessing the influence of age and gender on the phenotype of myotonic dystrophy type 2","volume":"264","author":"Montagnese","year":"2017","journal-title":"J Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib15","first-page":"126","article-title":"Multidimensional aspects of pain in myotonic dystrophies","volume":"34","author":"Peric","year":"2015","journal-title":"Acta Myol"},{"key":"10.1007\/s13311-018-00679-z_bib16","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/mus.24079","article-title":"Pain location and intensity impacts function in persons with myotonic dystrophy type 1 and facioscapulohumeral dystrophy with chronic pain","volume":"49","author":"Miro","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-00679-z_bib17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2340\/16501977-0833","article-title":"Feasibility and effects of a physical exercise programme in adults with myotonic dystrophy type 1: a randomized controlled pilot study","volume":"43","author":"Kierkegaard","year":"2011","journal-title":"J Rehabil Med"},{"key":"10.1007\/s13311-018-00679-z_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/PHM.0000000000000088","article-title":"Impact of habitual exercise on the strength of individuals with myotonic dystrophy type 1","volume":"93","author":"Brady","year":"2014","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1007\/s13311-018-00679-z_bib19","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0003-9993(95)80629-6","article-title":"Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial","volume":"76","author":"Lindeman","year":"1995","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1007\/s13311-018-00679-z_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ana.20460","article-title":"Aerobic training in patients with myotonic dystrophy type 1","volume":"57","author":"Orngreen","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mus.25233","article-title":"One clinic's experience with carbon fiber orthoses in neuromuscular disease","volume":"55","author":"Mnatsakanian","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-00679-z_bib22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/01.WNL.0000118206.49652.A3","article-title":"Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1","volume":"62","author":"Logigian","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-00679-z_bib23","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10072-016-2805-5","article-title":"Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects","volume":"38","author":"Meola","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-018-00679-z_bib24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.nmd.2015.01.006","article-title":"SCN4A mutation as modifying factor of myotonic dystrophy type 2 phenotype","volume":"25","author":"Bugiardini","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-00679-z_bib25","author":"Cardani"},{"key":"10.1007\/s13311-018-00679-z_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29302-z","article-title":"SCN4A as modifier gene in patients with myotonic dystrophy type 2","volume":"8","author":"Binda","year":"2018","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-018-00679-z_bib27","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1212\/WNL.0b013e3181dc1a3a","article-title":"Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1","volume":"74","author":"Logigian","year":"2010","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-00679-z_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ana.24331","article-title":"Sodium channel slow inactivation as a therapeutic target for myotonia congenita","volume":"77","author":"Novak","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib29","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004229","article-title":"Open-label trial of ranolazine for the treatment of myotonia congenita","author":"Arnold","year":"2017","journal-title":"Neurology"},{"issue":"15 Supplement","key":"10.1007\/s13311-018-00679-z_bib30","article-title":"Open label trial of ranolazine for the treatment of paramyotonia congenita (P3.436)","volume":"90","author":"LoRusso","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-00679-z_bib31","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/brain\/awx192","article-title":"The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study","volume":"140","author":"Andersen","year":"2017","journal-title":"Brain"},{"issue":"15 Supplement","key":"10.1007\/s13311-018-00679-z_bib32","article-title":"Investigation of ranolazine as an anti-myotonia treatment in myotonic dystrophy type 1 (P5.443)","volume":"90","author":"Lawless","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-00679-z_bib33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fncel.2017.00101","article-title":"Myotonic dystrophies: state of the art of new therapeutic developments for the CNS","volume":"11","author":"Gourdon","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"10.1007\/s13311-018-00679-z_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/arclin\/acq016","article-title":"Toward understanding cognitive impairment in patients with myotonic dystrophy type 1","volume":"25","author":"Zalonis","year":"2010","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1007\/s13311-018-00679-z_bib35","first-page":"43","article-title":"The proposal of a clinical protocol to assess central and peripheral fatigue in myotonic dystrophy type 1","volume":"155","author":"Baldanzi","year":"2017","journal-title":"Arch Ital Biol"},{"key":"10.1007\/s13311-018-00679-z_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/jnnp.46.7.625","article-title":"Contractile properties of muscles in myotonic dystrophy","volume":"46","author":"Belanger","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1007\/s13311-018-00679-z_bib37","article-title":"Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy","author":"Annane","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1007\/s13311-018-00679-z_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00415-006-0186-z","article-title":"Does modafinil enhance activity of patients with myotonic dystrophy?: a double-blind placebo-controlled crossover study","volume":"254","author":"Wintzen","year":"2007","journal-title":"J Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.nmd.2012.02.005","article-title":"Modafinil for excessive daytime sleepiness in myotonic dystrophy type 1\u2014the patients' perspective","volume":"22","author":"Hilton-Jones","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-00679-z_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clineuro.2014.08.021","article-title":"Significant impact of behavioral and cognitive impairment on quality of life in patients with myotonic dystrophy type 1","volume":"126","author":"Rakocevic-Stojanovic","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-018-00679-z_bib41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10072-016-2778-4","article-title":"Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2","volume":"38","author":"Peric","year":"2017","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-018-00679-z_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13023-014-0186-5","article-title":"Comparisons of intellectual capacities between mild and classic adult-onset phenotypes of myotonic dystrophy type 1 (DM1)","volume":"9","author":"Jean","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-018-00679-z_bib43","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/hmg\/10.19.2143","article-title":"Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1","volume":"10","author":"Sergeant","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-018-00679-z_bib44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pjnns.2015.04.008","article-title":"Peripheral nerve involvement in myotonic dystrophy type 2\u2014similar or different than in myotonic dystrophy type 1?","volume":"49","author":"Nojszewska","year":"2015","journal-title":"Neurol Neurochir Pol"},{"key":"10.1007\/s13311-018-00679-z_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1529-8027.2011.00313.x","article-title":"Peripheral neuropathy in myotonic dystrophy type 1","volume":"16","author":"Hermans","year":"2011","journal-title":"J Peripherl Nerv Syst"},{"key":"10.1007\/s13311-018-00679-z_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fphys.2013.00257","article-title":"Autonomic regulation in muscular dystrophy","volume":"4","author":"Angelini","year":"2013","journal-title":"Front Physiol"},{"key":"10.1007\/s13311-018-00679-z_bib47","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1212\/WNL.52.8.1658","article-title":"A 10-year study of mortality in a cohort of patients with myotonic dystrophy","volume":"52","author":"Mathieu","year":"1999","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-00679-z_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.resp.2014.01.006","article-title":"Supine changes in lung function correlate with chronic respiratory failure in myotonic dystrophy patients","volume":"193","author":"Poussel","year":"2014","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1007\/s13311-018-00679-z_bib49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.nmd.2015.01.011","article-title":"207th ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies: management and implications for research, 27\u201329 June 2014, Naarden, The Netherlands","volume":"25","author":"Sansone","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-00679-z_bib50","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.nmd.2015.02.006","article-title":"Lack of correlation between the ventilatory response to CO2 and lung function impairment in myotonic dystrophy patients: evidence for a dysregulation at central level","volume":"25","author":"Poussel","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-00679-z_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ane.12355","article-title":"Sleep and breathing disorders in myotonic dystrophy type 2","volume":"132","author":"Leonardis","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-018-00679-z_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nmd.2011.08.010","article-title":"Sleep breathing disorders in 40 Italian patients with Myotonic dystrophy type 1","volume":"22","author":"Pincherle","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-00679-z_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2017-210610","article-title":"Effect and impact of mechanical ventilation in myotonic dystrophy type 1: a prospective cohort study","author":"Boussaid","year":"2018","journal-title":"Thorax"},{"key":"10.1007\/s13311-018-00679-z_bib54","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/archinte.1967.00290200100008","article-title":"The heart in myotonia atrophica","volume":"119","author":"Church","year":"1967","journal-title":"Arch Intern Med"},{"key":"10.1007\/s13311-018-00679-z_bib55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ahj.2003.08.008","article-title":"Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I","volume":"147","author":"Bhakta","year":"2004","journal-title":"Am Heart J"},{"key":"10.1007\/s13311-018-00679-z_bib56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0735-1097(94)00351-P","article-title":"Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy","volume":"25","author":"Melacini","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-00679-z_bib57","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/heart.86.4.411","article-title":"Does cytosine-thymine-guanine (CTG) expansion size predict cardiac events and electrocardiographic progression in myotonic dystrophy?","volume":"86","author":"Clarke","year":"2001","journal-title":"Heart"},{"key":"10.1007\/s13311-018-00679-z_bib58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1542-474X.2003.08310.x","article-title":"Heart rate variability declines with increasing age and CTG repeat length in patients with myotonic dystrophy type 1","volume":"8","author":"Hardin","year":"2003","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1007\/s13311-018-00679-z_bib59","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1161\/01.CIR.60.6.1360","article-title":"The natural history of conduction system disease in myotonic muscular dystrophy as determined by serial electrophysiologic studies","volume":"60","author":"Prystowsky","year":"1979","journal-title":"Circulation"},{"key":"10.1007\/s13311-018-00679-z_bib60","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/heart.88.6.665","article-title":"Myotonic dystrophy and the heart","volume":"88","author":"Pelargonio","year":"2002","journal-title":"Heart"},{"key":"10.1007\/s13311-018-00679-z_bib61","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0735-1097(85)80286-2","article-title":"Ventricular tachycardia and sudden death in myotonic dystrophy: clinical, electrophysiologic and pathologic features","volume":"6","author":"Grigg","year":"1985","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-00679-z_bib62","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/01.CIR.98.6.541","article-title":"Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation","volume":"98","author":"Merino","year":"1998","journal-title":"Circulation"},{"key":"10.1007\/s13311-018-00679-z_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijcard.2015.03.069","article-title":"Myotonic dystrophy and the heart: a systematic review of evaluation and management","volume":"184","author":"Lau","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1007\/s13311-018-00679-z_bib64","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/jcp.31.11.1057","article-title":"Myotonia dystrophica with heart involvement: an electron microscopic study of skeletal, cardiac, and smooth muscle","volume":"31","author":"Ludatscher","year":"1978","journal-title":"J Clin Pathol"},{"key":"10.1007\/s13311-018-00679-z_bib65","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0002-9343(79)90795-2","article-title":"Cardiac abnormalities in myotonic dystrophy. Electrophysiologic and histopathologic studies","volume":"67","author":"Motta","year":"1979","journal-title":"Am J Med"},{"key":"10.1007\/s13311-018-00679-z_bib66","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0735-1097(88)91547-1","article-title":"Pathology of the cardiac conduction system in myotonic dystrophy: a study of 12 cases","volume":"11","author":"Nguyen","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-00679-z_bib67","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.ijcard.2012.11.076","article-title":"The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes","volume":"168","author":"Sansone","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1007\/s13311-018-00679-z_bib68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/heartjnl-2011-301407","article-title":"What is the best way to detect infra-Hisian conduction abnormalities and prevent sudden cardiac death in myotonic dystrophy?","volume":"98","author":"Duboc","year":"2012","journal-title":"Heart"},{"key":"10.1007\/s13311-018-00679-z_bib69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCIMAGING.110.960740","article-title":"Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations","volume":"4","author":"Verhaert","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1007\/s13311-018-00679-z_bib70","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1001\/jama.2012.346","article-title":"Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease","volume":"307","author":"Wahbi","year":"2012","journal-title":"JAMA"},{"key":"10.1007\/s13311-018-00679-z_bib71","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.0000000000004420","article-title":"High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2","volume":"89","author":"Hilbert","year":"2017","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-00679-z_bib72","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/jmg.29.11.791","article-title":"Intestinal pseudo-obstruction in myotonic dystrophy","volume":"29","author":"Brunner","year":"1992","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-018-00679-z_bib73","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/jnnp.64.1.128","article-title":"Faecal incontinence in myotonic dystrophy","volume":"64","author":"Abercrombie","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-018-00679-z_bib74","first-page":"88","article-title":"Faecal incontinence due to atrophy of the anal sphincter in myotonic dystrophy: a case report","volume":"74","author":"Degraeuwe","year":"2011","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1007\/s13311-018-00679-z_bib75","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3748\/wjg.v12.i12.1821","article-title":"Gastrointestinal manifestations in myotonic muscular dystrophy","volume":"12","author":"Bellini","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1007\/s13311-018-00679-z_bib76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02427560","article-title":"Positive correlation of CTG expansion and pharyngoesophageal alterations in myotonic dystrophy patients","volume":"19","author":"Marcon","year":"1998","journal-title":"Ital J Neurol Sci"},{"key":"10.1007\/s13311-018-00679-z_bib77","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mus.21787","article-title":"Bacterial overgrowth syndrome in myotonic muscular dystrophy is potentially treatable","volume":"42","author":"Tarnopolsky","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-00679-z_bib78","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.5301\/ejo.5000565","article-title":"Primary cataract as a key to recognition of myotonic dystrophy type 1","volume":"25","author":"Voermans","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"10.1007\/s13311-018-00679-z_bib79","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1172\/JCI105346","article-title":"Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism","volume":"45","author":"Wochner","year":"1966","journal-title":"J Clin Investig"},{"key":"10.1007\/s13311-018-00679-z_bib80","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clineuro.2011.02.003","article-title":"IgG deficiency and expansion of CTG repeats in myotonic dystrophy","volume":"113","author":"Kaminsky","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1007\/s13311-018-00679-z_bib81","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1001\/jama.2011.1796","article-title":"Cancer risk among patients with myotonic muscular dystrophy","volume":"306","author":"Gadalla","year":"2011","journal-title":"JAMA"},{"key":"10.1007\/s13311-018-00679-z_bib82","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/ene.12542","article-title":"Endocrine function over time in patients with myotonic dystrophy type 1","volume":"22","author":"Dahlqvist","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib83","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","article-title":"Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member","volume":"68","author":"Brook","year":"1992","journal-title":"Cell"},{"key":"10.1007\/s13311-018-00679-z_bib84","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/jmg.33.9.783","article-title":"Homozygous myotonic dystrophy: clinical and molecular studies of three unrelated cases","volume":"33","author":"Martorell","year":"1996","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-018-00679-z_bib85","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.410350116","article-title":"Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes","volume":"35","author":"Thornton","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib86","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/jmg.31.7.518","article-title":"Paternal transmission of congenital myotonic dystrophy","volume":"31","author":"Bergoffen","year":"1994","journal-title":"J Med Genet"},{"key":"10.1007\/s13311-018-00679-z_bib87","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ajmg.10141","article-title":"Paternal transmission of the congenital form of myotonic dystrophy type 1: a new case and review of the literature","volume":"107","author":"Zeesman","year":"2002","journal-title":"Am J Med Genet"},{"key":"10.1007\/s13311-018-00679-z_bib88","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ajhg.2017.01.033","article-title":"CpG methylation, a parent-of-origin effect for maternal-biased transmission of congenital myotonic dystrophy","volume":"100","author":"Barb\u00e9","year":"2017","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-018-00679-z_bib89","first-page":"414","article-title":"Characteristics of intergenerational contractions of the CTG repeat in myotonic dystrophy","volume":"54","author":"Ashizawa","year":"1994","journal-title":"Am J Hum Genet"},{"key":"10.1007\/s13311-018-00679-z_bib90","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S1355838200991544","article-title":"Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR","volume":"6","author":"Tian","year":"2000","journal-title":"RNA"},{"key":"10.1007\/s13311-018-00679-z_bib91","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/nar\/27.17.3534","article-title":"Visualization of double-stranded RNAs from the myotonic dystrophy protein kinase gene and interactions with CUG-binding protein","volume":"27","author":"Michalowski","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"10.1007\/s13311-018-00679-z_bib92","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1073\/pnas.0505873102","article-title":"The structural basis of myotonic dystrophy from the crystal structure of CUG repeats","volume":"102","author":"Mooers","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-018-00679-z_bib93","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fnagi.2015.00125","article-title":"Muscle wasting in myotonic dystrophies: a model of premature aging","volume":"7","author":"Mateos-Aierdi","year":"2015","journal-title":"Front Aging Neurosci"},{"key":"10.1007\/s13311-018-00679-z_bib94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fnmol.2013.00057","article-title":"Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy","volume":"6","author":"Caillet-Boudin","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"10.1007\/s13311-018-00679-z_bib95","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1212\/CON.0000000000000414","article-title":"The dystrophic and nondystrophic myotonias","volume":"22","author":"Sansone","year":"2016","journal-title":"Continuum (Minneapolis, Minn)"},{"key":"10.1007\/s13311-018-00679-z_bib96","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nm.2374","article-title":"Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy","volume":"17","author":"Fugier","year":"2011","journal-title":"Nat Med"},{"key":"10.1007\/s13311-018-00679-z_bib97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1097-2765(02)00572-5","article-title":"Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing","volume":"10","author":"Charlet-B","year":"2002","journal-title":"Mol Cell"},{"key":"10.1007\/s13311-018-00679-z_bib98","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1126\/science.280.5364.737","article-title":"Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy","volume":"280","author":"Philips","year":"1998","journal-title":"Science"},{"key":"10.1007\/s13311-018-00679-z_bib99","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/mus.20809","article-title":"Altered mRNA splicing of dystrophin in type 1 myotonic dystrophy","volume":"36","author":"Nakamori","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-00679-z_bib100","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ana.23992","article-title":"Splicing biomarkers of disease severity in myotonic dystrophy","volume":"74","author":"Nakamori","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib101","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.gde.2017.03.007","article-title":"Myotonic dystrophy: approach to therapy","volume":"44","author":"Thornton","year":"2017","journal-title":"Curr Opin Genet Dev"},{"key":"10.1007\/s13311-018-00679-z_bib102","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1073\/pnas.1013343108","article-title":"Non-ATG-initiated translation directed by microsatellite expansions","volume":"108","author":"Zu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-018-00679-z_bib103","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1093\/hmg\/ddt371","article-title":"Repeat-associated non-ATG (RAN) translation in neurological disease","volume":"22","author":"Cleary","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-018-00679-z_bib104","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.biochi.2011.06.028","article-title":"Gain of RNA function in pathological cases: focus on myotonic dystrophy","volume":"93","author":"Klein","year":"2011","journal-title":"Biochimie"},{"key":"10.1007\/s13311-018-00679-z_bib105","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1172\/JCI5346","article-title":"DMPK dosage alterations result in atrioventricular conduction abnormalities in a mouse myotonic dystrophy model","volume":"103","author":"Berul","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-018-00679-z_bib106","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng0897-407","article-title":"Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene","volume":"16","author":"Thornton","year":"1997","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-018-00679-z_bib107","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fneur.2018.00463","article-title":"Distribution and structure of DM2 repeat tract alleles in the German population","volume":"9","author":"Mahyera","year":"2018","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib108","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.3233\/JND-150088","article-title":"Myotonic dystrophy type 2: an update on clinical aspects, genetic and pathomolecular mechanism","volume":"2","author":"Meola","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"10.1007\/s13311-018-00679-z_bib109","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04370-x","article-title":"rbFOX1\/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1\/type 2 differences","volume":"9","author":"Sellier","year":"2018","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-018-00679-z_bib110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083777","article-title":"Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic dystrophy type 2","volume":"8","author":"Cardani","year":"2013","journal-title":"PLoS One"},{"key":"10.1007\/s13311-018-00679-z_bib111","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jmb.2007.01.088","article-title":"Haploinsuffciency for Znf9 in Znf9+\/\u2212 mice is associated with multiorgan abnormalities resembling myotonic dystrophy","volume":"368","author":"Chen","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1007\/s13311-018-00679-z_bib112","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2353\/ajpath.2010.100179","article-title":"Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2","volume":"177","author":"Raheem","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-018-00679-z_bib113","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/hmg\/ddl103","article-title":"DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression","volume":"15","author":"Margolis","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-018-00679-z_bib114","doi-asserted-by":"crossref","first-page":"1292.e5","DOI":"10.1016\/j.neuron.2017.08.039","article-title":"RAN translation regulated by muscleblind proteins in myotonic dystrophy type 2","volume":"95","author":"Zu","year":"2017","journal-title":"Neuron"},{"key":"10.1007\/s13311-018-00679-z_bib115","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","article-title":"CRISPR\/Cas9-induced (CTGCAG)n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing","volume":"25","author":"van Agtmaal","year":"2017","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-00679-z_bib116","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/mt.2011.191","article-title":"Stabilization of expanded (CTG)*(CAG) repeats by antisense oligonucleotides","volume":"19","author":"Nakamori","year":"2011","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-00679-z_bib117","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.celrep.2015.11.028","article-title":"Actinomycin D specifically reduces expanded CUG repeat RNA in myotonic dystrophy models","volume":"13","author":"Siboni","year":"2015","journal-title":"Cell Rep"},{"key":"10.1007\/s13311-018-00679-z_bib118","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/cts.12275","article-title":"Sodium channel inhibitors reduce DMPK mRNA and protein","volume":"8","author":"Witherspoon","year":"2015","journal-title":"Clin Transl Sci"},{"key":"10.1007\/s13311-018-00679-z_bib119","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1021\/cb400431f","article-title":"Reducing levels of toxic RNA with small molecules","volume":"8","author":"Coonrod","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1007\/s13311-018-00679-z_bib120","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/acn3.271","article-title":"Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy","volume":"3","author":"Nakamori","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib121","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1093\/nar\/gku275","article-title":"Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects","volume":"42","author":"Hoskins","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1007\/s13311-018-00679-z_bib122","article-title":"Phenylbutazone induces expression of MBNL1 and suppresses formation of MBNL1-CUG RNA foci in a mouse model of myotonic dystrophy","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-018-00679-z_bib123","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1073\/pnas.0604970103","article-title":"Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy","volume":"103","author":"Kanadia","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-018-00679-z_bib124","article-title":"GSK3beta is a new therapeutic target for myotonic dystrophy type 1","volume":"1","author":"Wei","year":"2013","journal-title":"Rare Diseases (Austin, Tex)"},{"key":"10.1007\/s13311-018-00679-z_bib125","series-title":"BEST (Biomarkers, EndpointS, and other Tools) resource","author":"Group F-NBW","year":"2016"},{"key":"10.1007\/s13311-018-00679-z_bib126","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-24156-x","article-title":"Quantitative methods to monitor RNA biomarkers in myotonic dystrophy","volume":"8","author":"Wojciechowska","year":"2018","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-018-00679-z_bib127","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nchembio.2251","article-title":"Precise small-molecule recognition of a toxic CUG RNA repeat expansion","volume":"13","author":"Rzuczek","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1007\/s13311-018-00679-z_bib128","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cmdc.201600081","article-title":"A potent inhibitor of protein sequestration by expanded triplet (CUG) repeats that shows phenotypic improvements in a Drosophila model of myotonic dystrophy","volume":"11","author":"Luu","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1007\/s13311-018-00679-z_bib129","doi-asserted-by":"crossref","first-page":"18551","DOI":"10.1073\/pnas.0903234106","article-title":"Pentamidine reverses the splicing defects associated with myotonic dystrophy","volume":"106","author":"Warf","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-018-00679-z_bib130","doi-asserted-by":"crossref","first-page":"14180","DOI":"10.1021\/jacs.5b09266","article-title":"Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1","volume":"137","author":"Nguyen","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1007\/s13311-018-00679-z_bib131","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1172\/JCI64081","article-title":"GSK3beta mediates muscle pathology in myotonic dystrophy","volume":"122","author":"Jones","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-018-00679-z_bib132","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/hmg\/ddt542","article-title":"High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines","volume":"23","author":"Ketley","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-018-00679-z_bib133","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","article-title":"Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation","volume":"28","author":"Kuyumcu-Martinez","year":"2007","journal-title":"Mol Cell"},{"key":"10.1007\/s13311-018-00679-z_bib134","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1172\/JCI89616","article-title":"Targeting deregulated AMPK\/mTORC1 pathways improves muscle function in myotonic dystrophy type I","volume":"127","author":"Brockhoff","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-018-00679-z_bib135","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/hmg\/ddu617","article-title":"TWEAK\/Fn14, a pathway and novel therapeutic target in myotonic dystrophy","volume":"24","author":"Yadava","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-018-00679-z_bib136","first-page":"22","article-title":"Antisense oligonucleotide-based therapy for neuromuscular disease","author":"Sardone","year":"2017","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1007\/s13311-018-00679-z_bib137","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1126\/science.1173110","article-title":"Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA","volume":"325","author":"Wheeler","year":"2009","journal-title":"Science"},{"key":"10.1007\/s13311-018-00679-z_bib138","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature11362","article-title":"Targeting nuclear RNA for in vivo correction of myotonic dystrophy","volume":"488","author":"Wheeler","year":"2012","journal-title":"Nature"},{"key":"10.1007\/s13311-018-00679-z_bib139","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","article-title":"Targeting DMPK with antisense oligonucleotide improves muscle strength in myotonic dystrophy type 1 mice","volume":"7","author":"Jauvin","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1007\/s13311-018-00679-z_bib140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/jpet.115.226969","article-title":"Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1","volume":"355","author":"Pandey","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-018-00679-z_bib141","doi-asserted-by":"crossref","first-page":"16949","DOI":"10.1074\/jbc.M501591200","article-title":"Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells","volume":"280","author":"Langlois","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-018-00679-z_bib142","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/mt.2012.222","article-title":"RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy","volume":"21","author":"Sobczak","year":"2013","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-00679-z_bib143","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jamaneurol.2016.3388","article-title":"Genome editing of monogenic neuromuscular diseases: a systematic review","volume":"73","author":"Long","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-018-00679-z_bib144","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.omtn.2017.10.006","article-title":"CRISPR\/Cas9-mediated deletion of CTG expansions recovers normal phenotype in myogenic cells derived from myotonic dystrophy 1 patients","volume":"9","author":"Provenzano","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1007\/s13311-018-00679-z_bib145","doi-asserted-by":"crossref","first-page":"899.e10","DOI":"10.1016\/j.cell.2017.07.010","article-title":"Elimination of toxic microsatellite repeat expansion RNA by Rna-Targeting Cas9","volume":"170","author":"Batra","year":"2017","journal-title":"Cell"},{"key":"10.1007\/s13311-018-00679-z_bib146","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/mt.2016.97","article-title":"Genome therapy of myotonic dystrophy type 1 iPS cells for development of autologous stem cell therapy","volume":"24","author":"Gao","year":"2016","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-00679-z_bib147","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/stem.1970","article-title":"Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells","volume":"33","author":"Xia","year":"2015","journal-title":"Stem Cells (Dayton, Ohio)"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-018-00679-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-00679-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-00679-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:36:38Z","timestamp":1775248598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":147,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1878747923010188"],"URL":"https:\/\/doi.org\/10.1007\/s13311-018-00679-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myotonic Dystrophies: Targeting Therapies for Multisystem Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-018-00679-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}